Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ruben A. G. van Eerden"'
Autor:
Ruben A. G. van Eerden, Leni van Doorn, Femke M. de Man, Niels Heersche, Michail Doukas, Thierry P. P. van den Bosch, Esther Oomen-de Hoop, Peter de Bruijn, Sander Bins, Eman Ibrahim, Suzan Nikkessen, Lena E. Friberg, Stijn L. W. Koolen, Manon C. W. Spaander, Ron H. J. Mathijssen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Data from previous work suggests that there is no correlation between systemic (plasma) paclitaxel exposure and efficacy in patients treated for esophageal cancer. In this trial, we investigated ATP-binding cassette efflux transporter exp
Externí odkaz:
https://doaj.org/article/2da8bb17075a4bb7a21f579be94bb87f
Autor:
Tessa A. M. Mulder, Ruben A. G. van Eerden, Mirjam de With, Laure Elens, Dennis A. Hesselink, Maja Matic, Sander Bins, Ron H. J. Mathijssen, Ron H. N. van Schaik
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the liver, responsible for the oxidative metabolism of ∼50% of clinically prescribed drugs. Therefore, genetic variation in CYP3A4 could potentially affect the pharmacok
Externí odkaz:
https://doaj.org/article/80b85a597c65408aa28ded486cfab7e7
Autor:
Ruben A. G. van Eerden, Esther Oomen-de Hoop, Aad Noordam, Ron H. J. Mathijssen, Stijn L. W. Koolen
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 119 (2021)
Small molecule kinase inhibitors (SMKIs) are widely used in oncology. Therapeutic drug monitoring (TDM) for SMKIs could reduce underexposure or overexposure. However, logistical issues such as timing of blood withdrawals hamper its implementation int
Externí odkaz:
https://doaj.org/article/9145dc98665a4501ad77c46a2e711500
Autor:
Ron H.J. Mathijssen, Ruben A G van Eerden, Femke M. de Man, Gerdien M van Doorn, Joris N. Veraart, Henk K van Halteren, Yorick Sandberg, Esther Oomen-de Hoop, Ron W. F. de Bruin, Stijn L.W. Koolen, Teun van Gelder, Adriaan Moelker, Martijn E.T. Dollé, Jan N. M. IJzermans, Joanne F. Olieman, Peter de Bruijn, Martijn P. Lolkema
Publikováno v:
Clinical Pharmacology and Therapeutics, 109(5), 1304-1313. Wiley-Blackwell
Preclinical data suggests that protein and calorie restriction (PCR) might improve treatment tolerability without impairing antitumor efficacy. Therefore, we have studied the influence of PCR on irinotecan pharmacokinetics and toxicity. In this cross
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abfd65e1ae87a83ad993df24d8e22649
http://www.scopus.com/inward/record.url?scp=85097045452&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85097045452&partnerID=8YFLogxK
Autor:
Ron H.J. Mathijssen, Martijn P. Lolkema, Stijn L.W. Koolen, Ruben A G van Eerden, Cristianne J.F. Rijcken, Marte A.M. van Hylckama Vlieg, Alex Sparreboom, Ferry A.L.M. Eskens, Florence Atrafi, Esther Oomen-de Hoop, Rob Hanssen, Adriaan Moelker, Peter de Bruijn
Publikováno v:
Clinical Cancer Research, 26(14), 3537-3545. American Association for Cancer Research Inc.
Purpose: CPC634 is a novel nanoparticle entrapping docetaxel, developed to enhance the intratumoral chemotherapy exposure. This randomized cross-over study compared the intratumoral and plasma pharmacokinetics of CPC634 with conventional docetaxel. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77ee1475ea1715c8d2117e42481df6b4
http://www.scopus.com/inward/record.url?scp=85087591926&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85087591926&partnerID=8YFLogxK
Autor:
Ruben A G van Eerden, Cristianne J.F. Rijcken, Ferry A.L.M. Eskens, Stijn L.W. Koolen, Martijn P. Lolkema, Peter de Bruijn, Florence Atrafi, Rob Hanssen, Ron H.J. Mathijssen, Jeffrey Damman, Esther Oomen-de Hoop
Publikováno v:
Cancers, Vol 13, Iss 3741, p 3741 (2021)
Cancers, 13(15):3741. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Cancers, 13(15):3741. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Simple Summary CPC634 is a nanoparticle entrapping docetaxel that is associated with skin toxicity that resembles conventional docetaxel-related skin toxicity. In this randomised cross-over study, the cutaneous pharmacokinetics and pharmacodynamics o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02af220cc2a5db71d2f54643cfa95b5
https://www.mdpi.com/2072-6694/13/15/3741
https://www.mdpi.com/2072-6694/13/15/3741
Publikováno v:
International Journal of Nanomedicine
International Journal of Nanomedicine, 15, 8151-8166. Dove Medical Press Ltd.
International Journal of Nanomedicine, 15, 8151-8166. Dove Medical Press Ltd.
Conventional taxanes are used as cornerstone of the chemotherapeutical treatment for a variety of malignancies. Nevertheless, a large proportion of patients do not benefit from their treatment while they do suffer from severe adverse events related t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8fb7c332664a48fb2be0919faf27831
https://pubmed.ncbi.nlm.nih.gov/33132699
https://pubmed.ncbi.nlm.nih.gov/33132699
Autor:
Alwin D. R. Huitema, Stefanie L. Groenland, Jos H. Beijnen, Niels de Vries, Bas Thijssen, Hilde Rosing, Ruben A G van Eerden, Stijn L.W. Koolen, Remy B. Verheijen, Ron H.J. Mathijssen, Neeltje Steeghs
Publikováno v:
Clinical Pharmacokinetics, 59(7), 941-948. Adis
Clinical Pharmacokinetics, 59(7), 941. Adis International Ltd
Clinical Pharmacokinetics, 59(7), 941. Adis International Ltd
Background and Objective: Pazopanib is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma and soft-tissue sarcoma. At the approved dose of 800 mg once daily (QD), 16–20% of patients are being underdosed and at risk of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8523041abf904f0a19949668d37b9b9e
https://pure.eur.nl/en/publications/31c7fb36-4788-426f-8676-2c471695966c
https://pure.eur.nl/en/publications/31c7fb36-4788-426f-8676-2c471695966c
Autor:
Remy B. Verheijen, Nielka P. van Erp, Stijn L.W. Koolen, Anna K.L. Reyners, Ruben A G van Eerden, Neeltje Steeghs, Ron H.J. Mathijssen, Ingrid M.E. Desar, Hans Gelderblom, Stefanie L. Groenland, Alwin D. R. Huitema, Dirk Jan A.R. Moes
Publikováno v:
Therapeutic Drug Monitoring, 41(5), 561-567. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring, 41(5), 561-567. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 41, 561-567
Therapeutic Drug Monitoring, 41(5), 561. Lippincott Williams and Wilkins
Therapeutic Drug Monitoring, 41, 5, pp. 561-567
Therapeutic Drug Monitoring, 41(5), 561-567. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 41, 561-567
Therapeutic Drug Monitoring, 41(5), 561. Lippincott Williams and Wilkins
Therapeutic Drug Monitoring, 41, 5, pp. 561-567
Item does not contain fulltext BACKGROUND: Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK), leading to large differences in drug exposure. For many of these drugs, exposure has been linked to efficacy and toxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcecc96f69f99850f826d4ac63c8ae88
https://hdl.handle.net/1887/122407
https://hdl.handle.net/1887/122407
Autor:
Femke M. de Man, Ron H.J. Mathijssen, Joris N. Veraart, Ate van der Gaast, Leni van Doorn, Ruben A G van Eerden, Esther Oomen-de Hoop, Nadia van Doorn
Publikováno v:
Cancers, Vol 11, Iss 6, p 826 (2019)
Cancers
Volume 11
Issue 6
Cancers, 11(6):826. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 11
Issue 6
Cancers, 11(6):826. Multidisciplinary Digital Publishing Institute (MDPI)
Many patients have advanced esophageal cancer at diagnosis. However, the most optimal treatment has not been identified. Therefore, we evaluated a weekly regimen of carboplatin (area under the curve (AUC)) of 4 and paclitaxel at 100 mg/m2 as an induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d2a327c1fb5d2ec464e94b7b69febd
https://www.mdpi.com/2072-6694/11/6/826
https://www.mdpi.com/2072-6694/11/6/826